Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): A pilot phase I/II trial

Annals of Oncology

Volumn 13, Issue 3, 2002, Pages 403-411

  Pottgen C ^a   Eberhardt, W ^a   Bildat, S ^a   Stuben G ^a   Stamatis, G ^a   Hillejan, L ^b   Sohrab, S ^b   Teschler, H ^a   Seeber, S ^a   Sack, H ^a   Stuschke, M ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b RUHRLANDKLINIK   (Germany)

Author keywords

Combined modality; Neoadjuvant; Non small cell lung cancer; Stage III

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ESOPHAGITIS; FEMALE; FEVER; HISTOLOGY; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKULL IRRADIATION; THROMBOCYTOPENIA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ADJUVANT THERAPY; AREA UNDER THE CURVE; LUNG TUMOR; LYMPH NODE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REMISSION; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; HUMAN; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGE; NEOADJUVANT THERAPY; NEOPLASM STAGING; PILOT PROJECTS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SURVIVAL RATE; HUMANS; MIDDLE AGED;

EID: 0036018909     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf050     Document Type: Article

References (40)

1. The role of surgery in N2 lung cancer
2. Mediastinal adenopathy - The N2 lesion
3. Should subcarinal lymph nodes be routinely examined in patients with non-small cell lung cancer?
4. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis
5. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small-cell lung cancer (NSCLC): A Hoosier Oncology Group (HOG) protocol
6. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
7. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients
8. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer
9. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
10. Combined-modality treatment of locally advanced non-small-cell lung cancer: Incorporation of novel chemotherapeutic agents
11. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
12. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer: A meta-analysis
13. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable non-small-cell lung cancer. A meta-analysis
14. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: A phase II study of the Lung Cancer Study Group
15. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study
16. Preoperative concomitant cisplatin/VP16 and radiotherapy in stage III non-small-cell lung cancer
17. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small-cell lung cancer
18. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIa (N2) and IIIb non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805
19. Pre-operative chemoradiotherapy in non-small-cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study
20. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer
21. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase II trial
22. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer
23. International clinical trials in radiation oncology. The late effects of toxicity scoring
24. Acute radiation morbidity scoring criteria (RTOG)
25. Nonparametric estimation from incomplete observations
26. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
27. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer
28. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial
29. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06
30. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small-cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410
31. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer
32. Biological target volume (BTV) determined with dose-response data from the correlation between metabolic rate of glucose (MRG) measured with 18F-FDG PET and pathologic complete response (pCR) in stage III non-small-cell lung cancer (NSCLC)
33. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium phase II trial
34. Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
35. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B non-small-cell lung carcinoma: A modified phase I trial
36. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC
37. Different fraction schedules and combinations with chemotherapy in radiation treatment of non-small-cell lung cancer
38. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORT
39. Combined-modality treatment for stage IIIa (N2) non-small-cell lung cancer: A National Cancer Institute Intergroup study